Stock

UK’s CMA may accept Synopsys/Ansys deal remedies

1 Mins read

Investing.com — The UK’s Competition and Markets Authority (CMA) said it may accept the remedies offered by Synopsys (NASDAQ:SNPS) and Ansys (NASDAQ:ANSS). The agency now has until until March 5, 2025 to make an official decision. The undertakings, offered by both companies at the end of last year on December 31, include the divestment of certain product lines.

Specifically, Ansys has proposed to divest its product for power consumption analysis of digital chips. On the other hand, Synopsys has offered to divest its Optical Solutions Group. The CMA has stated that there are reasonable grounds to believe that these undertakings might be accepted.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.